Literature DB >> 30097785

Incidence and risk factors for neovascular age-related macular degeneration in the fellow eye.

Toke Bek1, Sidsel Ehlers Klug2.   

Abstract

PURPOSE: The epidemiology, risk factors, and the effect of anti-VEGF treatment on neovascular age-related macular degeneration (nAMD) have primarily been studied in the first eye developing the disease. The understanding of pathophysiology and planning of follow-up examinations can be improved by knowledge of incidence and risk factors for development of the disease in the fellow eye.
METHODS: In a prospective observational cohort study, epidemiological and clinical risk factors for the development of nAMD in the fellow eye among 2516 patients consecutively diagnosed with the disease from a population of 0.9 million citizens during a period of more than 10 years were studied.
RESULTS: nAMD had been diagnosed in the fellow eye of 541 (21.5%) of the patients. The incidence of fellow-eye involvement increased from approximately 5% in patients initially presenting with bilateral disease to approximately 28% more than 6 years after the diagnosis in the first eye. Visual acuity (VA) was higher and central retinal thickness (CRT) was lower in fellow eyes with nAMD diagnosed later than the first eye. Male gender, increasing leakage area, and peripapillary location of the subretinal neovascular membrane in the first eye reduced the risk of developing disease in the fellow eye.
CONCLUSIONS: The planning of follow-up examinations of patients diagnosed with nAMD in one eye should consider that the risk of fellow-eye involvement is higher within the first 6 years, in women, and when the leakage area in the first eye is small and not located peripapillary.

Entities:  

Keywords:  Anti-VEGF treatment; Fellow eye; Neovascular age-related macular degeneration; Risk factors

Mesh:

Substances:

Year:  2018        PMID: 30097785     DOI: 10.1007/s00417-018-4100-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  28 in total

1.  Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration.

Authors:  Maria-Andreea Gamulescu; Horst Helbig
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

2.  Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.

Authors:  Jost B Jonas; Yong Tao; Florian Rensch
Journal:  J Ocul Pharmacol Ther       Date:  2011-08       Impact factor: 2.671

3.  Association of ARMS2 genotype with bilateral involvement of exudative age-related macular degeneration.

Authors:  Hiroshi Tamura; Akitaka Tsujikawa; Kenji Yamashiro; Yumiko Akagi-Kurashige; Isao Nakata; Hideo Nakanishi; Hisako Hayashi; Sotaro Ooto; Atsushi Otani; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2012-07-17       Impact factor: 5.258

4.  Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization.

Authors:  Agnes Boltz; Alexandra Luksch; Barbara Wimpissinger; Noemi Maar; Günther Weigert; Sophie Frantal; Werner Brannath; Gerhard Garhöfer; Erdem Ergun; Michael Stur; Leopold Schmetterer
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

5.  Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.

Authors:  Prema Abraham; Huibin Yue; Laura Wilson
Journal:  Am J Ophthalmol       Date:  2010-07-03       Impact factor: 5.258

6.  The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD).

Authors:  Samantha S Mann; Yvonne Rutishauser-Arnold; Tunde Peto; Sharon A Jenkins; Irene Leung; Wen Xing; Alan C Bird; Catey Bunce; Andrew R Webster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-08-25       Impact factor: 3.117

Review 7.  Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis.

Authors:  Alicja R Rudnicka; Zakariya Jarrar; Richard Wormald; Derek G Cook; Astrid Fletcher; Christopher G Owen
Journal:  Ophthalmology       Date:  2011-12-15       Impact factor: 12.079

8.  Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

Authors: 
Journal:  JAMA       Date:  2013-05-15       Impact factor: 56.272

9.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

Review 10.  Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis.

Authors:  Usha Chakravarthy; Tien Y Wong; Astrid Fletcher; Elisabeth Piault; Christopher Evans; Gergana Zlateva; Ronald Buggage; Andreas Pleil; Paul Mitchell
Journal:  BMC Ophthalmol       Date:  2010-12-13       Impact factor: 2.209

View more
  3 in total

1.  Predicting conversion to wet age-related macular degeneration using deep learning.

Authors:  Jason Yim; Reena Chopra; Terry Spitz; Jim Winkens; Annette Obika; Christopher Kelly; Harry Askham; Marko Lukic; Josef Huemer; Katrin Fasler; Gabriella Moraes; Clemens Meyer; Marc Wilson; Jonathan Dixon; Cian Hughes; Geraint Rees; Peng T Khaw; Alan Karthikesalingam; Dominic King; Demis Hassabis; Mustafa Suleyman; Trevor Back; Joseph R Ledsam; Pearse A Keane; Jeffrey De Fauw
Journal:  Nat Med       Date:  2020-05-18       Impact factor: 53.440

2.  Predicting wet age-related macular degeneration (AMD) using DARC (detecting apoptosing retinal cells) AI (artificial intelligence) technology.

Authors:  Paolo Corazza; John Maddison; Paolo Bonetti; Li Guo; Vy Luong; Alan Garfinkel; Saad Younis; Maria Francesca Cordeiro
Journal:  Expert Rev Mol Diagn       Date:  2020-12-28       Impact factor: 5.225

3.  Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration.

Authors:  Katrin Fasler; Dun Jack Fu; Gabriella Moraes; Siegfried Wagner; Eesha Gokhale; Karsten Kortuem; Reena Chopra; Livia Faes; Gabriella Preston; Nikolas Pontikos; Praveen J Patel; Adnan Tufail; Aaron Y Lee; Konstantinos Balaskas; Pearse A Keane
Journal:  Br J Ophthalmol       Date:  2019-10-14       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.